JAMA Netw Open

Semaglutide may protect against overdoses in patients with OUD

September 30, 2024

Compared with other antidiabetic medications, semaglutide was associated with a lower risk of opioid overdose in patients with comorbid T2DM and opioid use disorder (OUD).

• In this emulation target trial, patients with comorbid T2DM and OUD were classified into two groups: semaglutide (N=3,034; mean age, 57.4 years, 56.5% female) and other antidiabetic medications (N=29,972). The main outcome was opioid overdose.
• Semaglutide was associated with a significantly reduced risk of opioid overdose during the 1-year follow-up period compared with other antidiabetic medications, including other GLP-1RAs, insulin, DPP-4is, SGLT2is, and thiazolidinediones, with hazard ratios ranging from 0.32 to 0.58.

Source:

Wang W, et al. (2024, September 3). JAMA Netw Open. Semaglutide and Opioid Overdose Risk in Patients With Type 2 Diabetes and Opioid Use Disorder. https://pubmed.ncbi.nlm.nih.gov/39320894/